Author

Petra Lutterbuese

Observed name: P. Lutterbuese

Institution: Amgen (Germany)

Observed institution: Amgen (Germany)

ORCID: 0009-0004-5568-1496

Observed ORCID: 0009-0004-5568-1496

OpenAlex ID: A5010919531

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

2014 · Michael D Oberst, Stacy Fuhrmann, et al. · mAbs · 92

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

2008 · Maria Amann, Klaus Brischwein, et al. · Cancer Research · 88

Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2007 · Scott A. Hammond, Ralf Lutterbuese, et al. · Cancer Research · 82

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

2009 · Ralf Lutterbuese, Tobias Raum, et al. · Journal of Immunotherapy · 78

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

2008 · Maria Amann, Matthias Friedrich, et al. · Cancer Immunology Immunotherapy · 40

Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model

2006 · Petra Lutterbuese, Klaus Brischwein, et al. · Cancer Immunology Immunotherapy · 15

Abstract 3364: Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer

2020 · Julie M. Bailis, Petra Lutterbuese, et al. · Cancer Research · 10

Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN

2023 · Elizabeth Pham, Petra Lutterbuese, et al. · Cancer Research · 9

Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3

2007 · Patrick A. Baeuerle, Maria Amann, et al. · Molecular Cancer Therapeutics · 3

Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics

2025 · Smitha PS Pillai, Kaushik Datta, et al. · Regulatory Toxicology and Pharmacology · 2

Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models

2008 · Kathy Mulgrew, David J. Stewart, et al. · Cancer Research · 2

How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?

2025 · Petra Lutterbuese, Sandrine d’Argouges, et al. · Regulatory Toxicology and Pharmacology · 1

Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas

2010 · Stacy R. Fuhrmann, Maria Amann, et al. · Cancer Research · 1

Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4E and F from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4J from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4C and D from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4L from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4K from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4G and H from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4A and B from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Supplementary Video 4I from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct

2023 · Scott A. Hammond, Ralf Lutterbuese, et al.

Abstract 3524: A novel approach to targeting mutated colorectal adenocarcinomas with T cell-engaging CEA/CD3-bispecific BiTE investigational antibody MEDI-565

2012 · Michael D. Oberst, Stacy Fuhrmann, et al. · Cancer Research

Abstract #3247: In vitro pharmacological comparison of a carcinoembryonic antigen (CEA)/CD3 bispecific cynomolgus-reactive biosimilar BiTE antibody (CyS111) biosimilar with the clinical candidate MEDI-565 (MT111)

2009 · Michael D. Oberst, Kathy Mulgrew, et al. · Cancer Research

Works count: 27

Citation count: 423

H-index: 8

I10-index: 7